Antihistamine switch
This article was originally published in The Tan Sheet
Executive Summary
CDER expects to reach decision by year-end on whether to switch Rx low- and non-sedating antihistamines Claritin (Schering-Plough), Allegra (Aventis) and Zyrtec (Pfizer) without sponsor consent. In May, FDA's Nonprescription and Pulmonary-Allergy Drugs Advisory Committees found the drugs safe for use in an OTC setting. Issues related to sedation warnings on currently available OTC antihistamines were discussed at a joint FDA/NTSB meeting Nov. 14-15 (1"The Tan Sheet" Nov. 19, p. 3)...
You may also be interested in...
Sedating Drug “Operating Machinery” Warnings Need Clarification – FDAer
Label statements advising "use caution when operating machinery" do not adequately communicate the risks consumers face from potentially sedating or impairing drugs, an FDA rep said Nov. 15
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.